Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) EBT Margin (2016 - 2025)

Historic EBT Margin for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to 10.42%.

  • BeOne Medicines' EBT Margin rose 202300.0% to 10.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.67%, marking a year-over-year increase of 277400.0%. This contributed to the annual value of 13.99% for FY2024, which is 196000.0% up from last year.
  • As of Q3 2025, BeOne Medicines' EBT Margin stood at 10.42%, which was up 202300.0% from 7.57% recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' EBT Margin ranged from a high of 29.35% in Q3 2023 and a low of 320.4% during Q2 2021
  • In the last 5 years, BeOne Medicines' EBT Margin had a median value of 55.29% in 2023 and averaged 82.3%.
  • In the last 5 years, BeOne Medicines' EBT Margin skyrocketed by 7082400bps in 2021 and then crashed by -1475900bps in 2022.
  • BeOne Medicines' EBT Margin (Quarter) stood at 283.22% in 2021, then surged by 60bps to 113.38% in 2022, then skyrocketed by 51bps to 55.29% in 2023, then skyrocketed by 86bps to 7.57% in 2024, then skyrocketed by 238bps to 10.42% in 2025.
  • Its last three reported values are 10.42% in Q3 2025, 7.57% for Q2 2025, and 1.87% during Q1 2025.